List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6214316/publications.pdf Version: 2024-02-01

		30070	26613
229	12,673	54	107
papers	citations	h-index	g-index
000	000	000	0005
232	232	232	8935
all docs	docs citations	times ranked	citing authors

ΠΑΥΙΟ ΒΑΡΑΟ

#	Article	IF	CITATIONS
1	Importance of IGF-I levels in IVF: potential relevance for growth hormone (GH) supplementation. Journal of Assisted Reproduction and Genetics, 2022, 39, 409-416.	2.5	8
2	IVF outcomes of embryos with abnormal PGT-A biopsy previously refused transfer: a prospective cohort study. Human Reproduction, 2022, 37, 1194-1206.	0.9	24
3	We have reached a dead end for preimplantation genetic testing for aneuploidy. Human Reproduction, 2022, 37, 2730-2734.	0.9	22
4	Preliminary report of intraovarian injections of autologous platelet-rich plasma (PRP) in extremely poor prognosis patients with only oocyte donation as alternative: a prospective cohort study. Human Reproduction Open, 2022, 2022, .	5.4	9
5	Reconsidering the Polycystic Ovary Syndrome (PCOS). Biomedicines, 2022, 10, 1505.	3.2	15
6	In science truth ultimately wins, and PGT-A is no exception. Human Reproduction, 2022, 37, 2216-2218.	0.9	4
7	A form of secondary ovarian insufficiency (SOI) due to adrenal hypoandrogenism as new infertility diagnosis. Endocrine, 2021, 72, 260-267.	2.3	0
8	Commentary on two recently published formal guidelines on management of "mosaic―embryos after preimplantation genetic testing for aneuploidy (PGT-A). Reproductive Biology and Endocrinology, 2021, 19, 23.	3.3	11
9	Individualized Ovarian Stimulation in Patients with Advanced Maternal Age and Premature Ovarian Aging. , 2021, , 14-29.		0
10	Noninvasive preimplantation genetic testing for aneuploidy in spent culture medium as a substitute for trophectoderm biopsy. Fertility and Sterility, 2021, 115, 841-849.	1.0	9
11	Depletion of aneuploid cells in human embryos and gastruloids. Nature Cell Biology, 2021, 23, 314-321.	10.3	83
12	O-170 Predictive value of cytoplasmic granulation patterns during IVF in MII oocytes from young donors. Human Reproduction, 2021, 36, .	0.9	0
13	Predictive value of cytoplasmic granulation patterns during inÂvitro fertilization in metaphase II oocytes: part II, donor oocyte cycles. Fertility and Sterility, 2021, 116, 1330-1340.	1.0	2
14	Antimüllerian hormone–levels not written in stone. Fertility and Sterility, 2021, 116, 83-84.	1.0	1
15	Time associations between U.S. birth rates and add-Ons to IVF practice between 2005–2016. Reproductive Biology and Endocrinology, 2021, 19, 110.	3.3	3
16	P–598 Further evidence for a functional hormonal adrenal-ovarian axis affecting female infertility. Human Reproduction, 2021, 36, .	0.9	0
17	O-176 Secondary ovarian insufficiency (SOI) - a new infertility diagnosis. Human Reproduction, 2021, 36,	0.9	0
18	P–199 A case report to suggest that there must be other mutations than PATL2 or TUBB8 to cause occyte maturation arrest. Human Reproduction, 2021, 36, .	0.9	0

#	Article	IF	CITATIONS
19	P–666 Validating the hypo-androgenic PCOS-like phenotype (H-PCOS), derived from the "lean―PCOS phenotype at younger ages. Human Reproduction, 2021, 36, .	0.9	0
20	Predictive value of cytoplasmic granulation patterns during inÂvitro fertilization in metaphase II oocytes: Part I, poor-prognosis patients. Fertility and Sterility, 2021, 116, 431-443.	1.0	7
21	Depletion of Aneuploid Cells in Human Embryos and Gastruloids. Obstetrical and Gynecological Survey, 2021, 76, 480-481.	0.4	2
22	A PILOT STUDY OF OOCYTE PRODUCTION AND ENDOCRINE RESPONSE AFTER INTRAOVARIAN TREATMENT WITH PLATELET-RICH PLASMA (PRP) IN INFERTILE WOMEN OF VERY ADVANCED AGE. Fertility and Sterility, 2021, 116, e242.	1.0	0
23	VALIDATION OF DIAGNOSTIC CRITERIA AND ANDROGEN SUPPLEMENTATION AS TREATMENT IN WOMEN WITH THE HYPOANDROGENIC PCOS-LIKE PHENOTYPE (H-PCOS). Fertility and Sterility, 2021, 116, e126.	1.0	0
24	THE SEX OF PRIOR PREGNANCIES AFFECTS THE RISK OF PRIMARY OVARIAN INSUFFICIENCY. Fertility and Sterility, 2021, 116, e112.	1.0	0
25	A CASE REPORT SUGGESTS THAT NOVEL HETHEROZYGOUS MUTATION OF ITGB3 GENE IS RESPONSIBLE TO PARTIAL OOCYTE MATURATION ARREST SYNDROME. Fertility and Sterility, 2021, 116, e150.	1.0	0
26	Rate of rebound in follicle growth after cessation of ovarian stimulation in initial nonâ€responders: a prospective cohort study. Journal of Ovarian Research, 2021, 14, 11.	3.0	0
27	ENDOCRINE EFFECTS OF INTRAOVARIAN INJECTION OF PLATELET-RICH PLASMA (PRP) IN WOMEN WITH PREMATURE OVARIAN AGING. Fertility and Sterility, 2020, 114, e89.	1.0	2
28	SELF-CORRECTION OF MOSAICISM IN HUMAN SELF-ORGANIZING GASTRULOIDS AS POTENTIAL EXPLANATION FOR NORMAL BIRTHS AFTER TRANSFER OF CHROMOSOMAL-ABNORMAL EMBRYOS. Fertility and Sterility, 2020, 114, e14-e15.	1.0	3
29	UNIQUE SUBCELLULAR CO-LOCALIZATION OF FMR1 WITH FIBRILLARIN AND AMH IN GRANULOSA CELLS SUGGESTS NOVEL ROLES IN LOCALIZED REGULATION OF CELL CYCLE PROGRESSION. Fertility and Sterility, 2020, 114, e344-e345.	1.0	0
30	IS IMMUNOGLOBULIN IgE RELEVANT FOR PREGNANCY LOSS?. Fertility and Sterility, 2020, 114, e356.	1.0	0
31	TRANSFER OF CHROMOSOMAL-ABNORMAL EMBRYOS, PREVIOUSLY REFUSED SUCH TRANSFERS. Fertility and Sterility, 2020, 114, e162-e163.	1.0	0
32	SUPRISING RATE OF REBOUND IN FOLLICLE GROWTH AFTER CESSATION OF OVAIAN STIMULATION IN INITIAL NON-RESPONDERS. Fertility and Sterility, 2020, 114, e163.	1.0	0
33	SYSTEMIC CATEGORIZATION OF OOCYTE GRANULATION PATTERNS AND THEIR PREDICTIVE VALUE FOR IVF OUTCOMES. Fertility and Sterility, 2020, 114, e289-e290.	1.0	0
34	DO INSULIN-LIKE GROWTH FACTOR (IGF-1) LEVELS IN INFERTILITY PATIENTS AFFECT IVF OUTCOMES?. Fertility and Sterility, 2020, 114, e326-e327.	1.0	0
35	The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A. Reproductive Biology and Endocrinology, 2020, 18, 57.	3.3	43
36	Why is use of donor eggs not viewed as treatment failure? A call for improvements in treatments with autologous oocytes. Journal of Assisted Reproduction and Genetics, 2020, 37, 1583-1588.	2.5	6

#	Article	IF	CITATIONS
37	Euploid miscarriage is associated with elevated serum C-reactive protein levels in infertile women: a pilot study. Archives of Gynecology and Obstetrics, 2020, 301, 831-836.	1.7	4
38	The ovarian sensitivity index is predictive of live birth chances after IVF in infertile patients. Human Reproduction Open, 2020, 2020, hoaa049.	5.4	16
39	Hormonal Effects in Reproductive Technology with Focus on Diminished Ovarian Reserve. Advances in Experimental Medicine and Biology, 2020, 1242, 13-36.	1.6	1
40	Worldwide decline of IVF birth rates and its probable causes. Human Reproduction Open, 2019, 2019, hoz017.	5.4	87
41	Age, body weight and ovarian function affect oocyte size and morphology in non-PCOS patients undergoing intracytoplasmic sperm injection (ICSI). PLoS ONE, 2019, 14, e0222390.	2.5	10
42	Worldwide live births following the transfer of chromosomally "Abnormal―embryos after PGT/A: results of a worldwide web-based survey. Journal of Assisted Reproduction and Genetics, 2019, 36, 1599-1607.	2.5	62
43	Changes in U.S. utilization of donor egg IVF cycles at different female ages between 2005-2016. Fertility and Sterility, 2019, 112, e120.	1.0	0
44	Not even noninvasive cell-free DNA can rescue preimplantation genetic testing. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21976-21977.	7.1	15
45	Transferring selected embryos, after PGT-A diagnosed as "abnormal,―where patients were refused such transfers at their original IVF centers. Fertility and Sterility, 2019, 112, e235.	1.0	0
46	Assessing in-vitro fertilisation at age 40 years. Lancet, The, 2019, 393, 1181-1183.	13.7	5
47	Effects of dehydroepiandrosterone (DHEA) supplementation on sexual function in premenopausal infertile women. Endocrine, 2019, 63, 632-638.	2.3	4
48	The Ovarian Factor in Assisted Reproductive Technology. , 2019, , 379-401.		2
49	Hypothesis: does exposure to sperm lead to pregnancy?. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 226-226.	2.3	0
50	Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age. Endocrine, 2018, 59, 661-676.	2.3	14
51	With low ovarian reserve, Highly Individualized Egg Retrieval (HIER) improves IVF results by avoiding premature luteinization. Journal of Ovarian Research, 2018, 11, 23.	3.0	23
52	Impact of androgen supplementation on the follicular endocrine milieu in women with hypoandrogenism. Reproductive BioMedicine Online, 2018, 36, 719-720.	2.4	2
53	Age-Specific IVF Outcomes in Infertile Women With Baseline FSH Levels ≥20 mIU/mL. Reproductive Sciences, 2018, 25, 893-898.	2.5	10
54	Observational retrospective study of US national utilisation patterns and live birth rates for various ovarian stimulation protocols for in vitro fertilisation. BMJ Open, 2018, 8, e023124.	1.9	7

#	Article	IF	CITATIONS
55	Reduced RNA expression of the FMR1 gene in women with low (CGGn<26) repeats. PLoS ONE, 2018, 13, e0209309.	2.5	10
56	Unexplained infertility. Lancet, The, 2018, 392, 1516-1517.	13.7	3
57	Vitamin D levels are not associated with ovarian reserve in a group of infertile women with a high prevalance of diminished ovarian reserve. Fertility and Sterility, 2018, 110, 761-766.e1.	1.0	22
58	Older women using their own eggs? Issue framed with two oldest reported IVF pregnancies and a live birth. Reproductive BioMedicine Online, 2018, 37, 172-177.	2.4	17
59	How PGS/PGT-A laboratories succeeded in losing all credibility. Reproductive BioMedicine Online, 2018, 37, 242-245.	2.4	27
60	Degree of mosaicism in trophectoderm does not predict pregnancy potential: a corrected analysis of pregnancy outcomes following transfer of mosaic embryos. Reproductive Biology and Endocrinology, 2018, 16, 6.	3.3	43
61	New national outcome data on fresh versus cryopreserved donor oocytes. Journal of Ovarian Research, 2018, 11, 2.	3.0	42
62	Systematic review of worldwide trends in assisted reproductive technology 2004–2013. Reproductive Biology and Endocrinology, 2017, 15, 6.	3.3	251
63	Redirecting reproductive immunology research toward pregnancy as a period of temporary immune tolerance. Journal of Assisted Reproduction and Genetics, 2017, 34, 425-430.	2.5	21
64	Response to comment on: Gleicher N et al., 2016. Reprod biol endocrinol Sep 5;14(1):54. Reproductive Biology and Endocrinology, 2017, 15, 23.	3.3	5
65	Elective single-embryo transfer (eSET) reduces pregnancy rates and should only be used in exceptional circumstances. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 755-755.	2.3	3
66	New PCOS-like phenotype in older infertile women of likely autoimmune adrenal etiology with high AMH but low androgens. Journal of Steroid Biochemistry and Molecular Biology, 2017, 167, 144-152.	2.5	20
67	Impact of preimplantation genetic screening on donor oocyte-recipient cycles in the United States. American Journal of Obstetrics and Gynecology, 2017, 217, 576.e1-576.e8.	1.3	21
68	First birth following spindle transfer. Reproductive BioMedicine Online, 2017, 35, 542-543.	2.4	11
69	Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. Journal of Assisted Reproduction and Genetics, 2017, 34, 1105-1113.	2.5	42
70	Association of skewed X-chromosome inactivation with FMR1 CGG repeat length and anti-Mullerian hormone levels: a cohort study. Reproductive Biology and Endocrinology, 2017, 15, 34.	3.3	4
71	A single trophectoderm biopsy at blastocyst stage is mathematically unable to determine embryo ploidy accurately enough for clinical use. Reproductive Biology and Endocrinology, 2017, 15, 33.	3.3	87
72	Effect of race and ethnicity on utilization and outcomes of assisted reproductive technology in the USA. Reproductive Biology and Endocrinology, 2017, 15, 44.	3.3	48

#	Article	IF	CITATIONS
73	Utilization of third-party inÂvitro fertilization in the UnitedÂStates. American Journal of Obstetrics and Gynecology, 2017, 216, 266.e1-266.e10.	1.3	17
74	Focus on recurrent miscarriage phenotypes. Fertility and Sterility, 2017, 107, 64-65.	1.0	8
75	Letter to the Editor: Including the Zona Reticularis in the Definition of Hypoadrenalism and Hyperadrenalism. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3569-3570.	3.6	2
76	CDC-reported assisted reproductive technology live-birth rates may mislead the public. Reproductive BioMedicine Online, 2017, 35, 161-164.	2.4	5
77	IVF outcomes in average- and poor-prognosis infertile women according to the number of embryos transferred. Reproductive BioMedicine Online, 2016, 33, 370-375.	2.4	10
78	Systemic Inflammation and Autoimmunity in Women with Chronic Endometritis. American Journal of Reproductive Immunology, 2016, 75, 672-677.	1.2	78
79	Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. Journal of Translational Medicine, 2016, 14, 172.	4.4	36
80	Associations between peripheral androgens and cortisol in infertile women. Journal of Steroid Biochemistry and Molecular Biology, 2016, 158, 82-89.	2.5	12
81	Improvements in IVF in women of advanced age. Journal of Endocrinology, 2016, 230, F1-F6.	2.6	53
82	Accuracy of preimplantation genetic screening (PGS) is compromised by degree of mosaicism of human embryos. Reproductive Biology and Endocrinology, 2016, 14, 54.	3.3	89
83	Antiâ€mullerian hormone levels decline with the presence of antiphospholipid antibodies. American Journal of Reproductive Immunology, 2016, 76, 333-337.	1.2	20
84	In reference to â€~Strategies to manage refractory endometrium: state of the art 2016'. Reproductive BioMedicine Online, 2016, 33, 604.	2.4	1
85	How FSH and AMH reflect probabilities of oocyte numbers in poor prognosis patients with small oocyte yields. Endocrine, 2016, 54, 476-483.	2.3	11
86	The importance of redundancy of functional ovarian reserve when investigating potential genetic effects on ovarian function. Journal of Assisted Reproduction and Genetics, 2016, 33, 1157-1160.	2.5	3
87	The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency. Reproductive Biology and Endocrinology, 2016, 14, 23.	3.3	17
88	Why Prospectively Randomized Clinical Trials Have Been Rare in Reproductive Medicine and Will Remain So?. Reproductive Sciences, 2016, 23, 6-10.	2.5	11
89	Randomized controlled trial of minimal stimulation versus conventional inÂvitro fertilization. American Journal of Obstetrics and Gynecology, 2016, 214, 412-413.	1.3	0
90	The impact of patient preselection on reported IVF outcomes. Journal of Assisted Reproduction and Genetics, 2016, 33, 455-459.	2.5	11

#	Article	IF	CITATIONS
91	Effectiveness of inÂvitro fertilization with preimplantation genetic screening: a reanalysis of United States assisted reproductive technology data 2011–2012. Fertility and Sterility, 2016, 106, 75-79.	1.0	56
92	Rescue in vitro maturation (IVM) of immature oocytes in stimulated cycles in women with low functional ovarian reserve (LFOR). Endocrine, 2016, 52, 165-171.	2.3	41
93	Effect of Embryo Banking on U.S. National Assisted Reproductive Technology Live Birth Rates. PLoS ONE, 2016, 11, e0154620.	2.5	20
94	Is there an androgen level threshold for aneuploidy risk in infertile women?. Reproductive Biology and Endocrinology, 2015, 13, 38.	3.3	4
95	The impact of thyroid function and thyroid autoimmunity on embryo quality in women with low functional ovarian reserve: a case-control study. Reproductive Biology and Endocrinology, 2015, 13, 43.	3.3	48
96	Advanced Reproductive Age and Maternal Mortality. Obstetrics and Gynecology, 2015, 125, 984.	2.4	1
97	Oocyte Scoring Enhances Embryo-Scoring in Predicting Pregnancy Chances with IVF Where It Counts Most. PLoS ONE, 2015, 10, e0143632.	2.5	85
98	Prospectively assessing risk for premature ovarian senescence in young females: a new paradigm. Reproductive Biology and Endocrinology, 2015, 13, 34.	3.3	33
99	Early decline in functional ovarian reserve in young women with low (CGGn < 26) FMR1 gene alleles. Translational Research, 2015, 166, 502-507.e2.	5.0	22
100	More on the conversion of DHEA to testosterone. Nature Reviews Endocrinology, 2015, 11, 521-521.	9.6	1
101	CDC analysis of ICSI/autism: association is not causation. Human Reproduction, 2015, 30, 1745-1746.	0.9	4
102	Some aspects of interactivity between endocrine and immune systems required for successful reproduction. Reproductive Biology and Endocrinology, 2015, 13, 29.	3.3	4
103	Genetics of androgen metabolism in women with infertility and hypoandrogenism. Nature Reviews Endocrinology, 2015, 11, 429-441.	9.6	25
104	Outcomes of Fresh and Cryopreserved Oocyte Donation. JAMA - Journal of the American Medical Association, 2015, 314, 623.	7.4	35
105	Relative importance of AMH and androgens changes with aging among non-obese women with polycystic ovary syndrome. Journal of Ovarian Research, 2015, 8, 45.	3.0	14
106	Aging-related premature luteinization of granulosa cells is avoided by early oocyte retrieval. Journal of Endocrinology, 2015, 226, 167-180.	2.6	69
107	Live-birth rates in very poor prognosis patients, who are defined as poor responders under the Bologna criteria, with nonelective single embryo, two-embryo, and three or more embryos transferred. Fertility and Sterility, 2015, 104, 1435-1441.	1.0	26
108	Utilizing FMR1 Gene Mutations as Predictors of Treatment Success in Human In Vitro Fertilization. PLoS ONE, 2014, 9, e102274.	2.5	20

#	Article	IF	CITATIONS
109	Do BRCA1/2 mutations and low FMR1 alleles interact or not?. European Journal of Human Genetics, 2014, 22, 155-156.	2.8	3
110	Ovarian reserve screening before contraception?. Reproductive BioMedicine Online, 2014, 29, 527-529.	2.4	15
111	How the FMR1 gene became relevant to female fertility and reproductive medicine. Frontiers in Genetics, 2014, 5, 284.	2.3	17
112	Preimplantation genetic screening (PCS) still in search of a clinical application: a systematic review. Reproductive Biology and Endocrinology, 2014, 12, 22.	3.3	81
113	Endocrine autoimmune diseases and female infertility. Nature Reviews Endocrinology, 2014, 10, 37-50.	9.6	92
114	Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and <i>microRNA-125b</i> expression. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3008-3013.	7.1	240
115	Poor responders and androgen adjuvant treatment: "Still haven't found what I'm looking for …― Reproductive BioMedicine Online, 2014, 29, 650-652.	2.4	7
116	The "graying―of infertility services: an impending revolution nobody is ready for. Reproductive Biology and Endocrinology, 2014, 12, 63.	3.3	40
117	Effect of inter-cycle interval on oocyte production in humans in the presence of the weak androgen DHEA and follicle stimulating hormone: a case-control study. Reproductive Biology and Endocrinology, 2014, 12, 68.	3.3	5
118	A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in inÂvitro fertilization cycles: impact on endometrial thickness and clinical pregnancy rates. Fertility and Sterility, 2014, 101, 710-715.	1.0	117
119	Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. PLoS ONE, 2014, 9, e102370.	2.5	8
120	ls androgen production in association with immune system activation potential evidence for existence of a functional adrenal/ovarian autoimmune system in women?. Reproductive Biology and Endocrinology, 2013, 11, 58.	3.3	7
121	Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? - A pilot study. Reproductive Biology and Endocrinology, 2013, 11, 28.	3.3	21
122	A pilot trial of large versus small diameter needles for oocyte retrieval. Reproductive Biology and Endocrinology, 2013, 11, 22.	3.3	5
123	FMR1-dependent variability of ovarian aging patterns is already apparent in young oocyte donors. Reproductive Biology and Endocrinology, 2013, 11, 80.	3.3	13
124	Hypoandrogenism in association with diminished functional ovarian reserve. Human Reproduction, 2013, 28, 1084-1091.	0.9	94
125	Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). Journal of Assisted Reproduction and Genetics, 2013, 30, 49-62.	2.5	49
126	A pilot cohort study of granulocyte colony-stimulating factor in the treatment of unresponsive thin endometrium resistant to standard therapies. Human Reproduction, 2013, 28, 172-177.	0.9	141

#	Article	IF	CITATIONS
127	Age at menarche: a predictor of diminished ovarian function?. Fertility and Sterility, 2013, 100, 1039-1043.	1.0	35
128	The status of public reporting ofÂclinical outcomes in assisted reproductive technology. Fertility and Sterility, 2013, 100, 736-741.e2.	1.0	46
129	Therapeutic Interventions into Early Stages of Follicle Maturation: A New Treatment Paradigm After Over 50 Years of Modern Infertility Therapy. Endocrinology, 2013, 154, 3498-3501.	2.8	6
130	Clinical Relevance of Combined FSH and AMH Observations in Infertile Women. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2136-2145.	3.6	14
131	Toward a Better Understanding of Functional Ovarian Reserve: AMH (AMHo) and FSH (FSHo) Hormone Ratios per Retrieved Oocyte. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 995-1004.	3.6	14
132	Intermediate and normal sized CGG repeat on the FMR1 gene does not negatively affect donor ovarian response. Human Reproduction, 2012, 27, 2241-2242.	0.9	4
133	A review of, and commentary on, the ongoing second clinical introduction of preimplantation genetic screening (PGS) to routine IVF practice. Journal of Assisted Reproduction and Genetics, 2012, 29, 1159-1166.	2.5	38
134	A case–control pilot study of low-intensity IVF in good-prognosis patients. Reproductive BioMedicine Online, 2012, 24, 396-402.	2.4	16
135	Hype or hope? Ethical and practical considerations with clinical research in women with diminished ovarian reserve. Reproductive BioMedicine Online, 2012, 25, 98-102.	2.4	4
136	The impact of androgen metabolism and FMR1 genotypes on pregnancy potential in women with dehydroepiandrosterone (DHEA) supplementation. Human Reproduction, 2012, 27, 3287-3293.	0.9	27
137	Cutting edge assessment of the impact of autoimmunity on female reproductive success. Journal of Autoimmunity, 2012, 38, J74-J80.	6.5	28
138	Lessons from elective in vitro fertilization (IVF) in, principally, non-infertile women. Reproductive Biology and Endocrinology, 2012, 10, 48.	3.3	17
139	Differences in ovarian aging patterns between races are associated with ovarian genotypes and sub-genotypes of the FMR1 gene. Reproductive Biology and Endocrinology, 2012, 10, 77.	3.3	33
140	The Impact in Older Women of Ovarian FMR1 Genotypes and Sub-Genotypes on Ovarian Reserve. PLoS ONE, 2012, 7, e33638.	2.5	23
141	BRCA1/2 Mutations Appear Embryo-Lethal Unless Rescued by Low (CGG n<26) FMR1 Sub-Genotypes: Explanation for the "BRCA Paradox�. PLoS ONE, 2012, 7, e44753.	2.5	29
142	Comparison of ovarian FMR1 genotypes and sub-genotypes in oocyte donors and infertile women. Journal of Assisted Reproduction and Genetics, 2012, 29, 529-532.	2.5	6
143	Follicle Stimulating Hormone and Anti-Müllerian Hormone per Oocyte in Predicting in vitro Fertilization Pregnancy in High Responders: A Cohort Study. PLoS ONE, 2012, 7, e34290.	2.5	7
144	Successful treatment of unresponsive thin endometrium. Fertility and Sterility, 2011, 95, 2123.e13-2123.e17.	1.0	144

#	Article	IF	CITATIONS
145	Utility of age-specific serum anti-Müllerian hormone concentrations. Reproductive BioMedicine Online, 2011, 22, 284-291.	2.4	60
146	Low-intensity IVF: real progress?. Reproductive BioMedicine Online, 2011, 23, 274-278.	2.4	9
147	Association of FMR1 Genotypes with In Vitro Fertilization (IVF) Outcomes Based on Ethnicity/Race. PLoS ONE, 2011, 6, e18781.	2.5	54
148	Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause, 2011, 18, 1160-1171.	2.0	76
149	Do chromosomally abnormal pregnancies really preclude autoimmune etiologies of spontaneous miscarriages?. Autoimmunity Reviews, 2011, 10, 361-363.	5.8	4
150	The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?. Reproductive Biology and Endocrinology, 2011, 9, 116.	3.3	136
151	Defining ovarian reserve to better understand ovarian aging. Reproductive Biology and Endocrinology, 2011, 9, 23.	3.3	148
152	Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reproductive Biology and Endocrinology, 2011, 9, 67.	3.3	169
153	Anti-Mullerian hormone levels decline under hormonal suppression: a prospective analysis in fertile women after delivery. Reproductive Biology and Endocrinology, 2011, 9, 98.	3.3	15
154	Live birth chances in women with extremely low-serum anti-Mullerian hormone levels. Human Reproduction, 2011, 26, 1905-1909.	0.9	69
155	Gestational Dermatosis Shortly after Implantation Associated with Parental Class II HLA Compatibility and Maternal Immune Activation: Preliminary Report of a Prospective Case Series. Dermatology, 2011, 222, 206-211.	2.1	4
156	The FMR1 Gene as Regulator of Ovarian Recruitment and Ovarian Reserve. Obstetrical and Gynecological Survey, 2010, 65, 523-530.	0.4	35
157	Can egg donor selection be improved? - a pilot study. Reproductive Biology and Endocrinology, 2010, 8, 76.	3.3	4
158	Can the FMR1 Gene Predict Early Ovarian Aging?. Women's Health, 2010, 6, 165-169.	1.5	6
159	Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reproductive Biology and Endocrinology, 2010, 8, 140.	3.3	87
160	Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility. Reproductive Biology and Endocrinology, 2010, 8, 64.	3.3	47
161	Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertility and Sterility, 2010, 94, 2824-2827.	1.0	117
162	Effects of race/ethnicity on triple CGG counts in the FMR1 gene in infertile women and egg donors. Reproductive BioMedicine Online, 2010, 20, 485-491.	2.4	43

#	Article	IF	CITATIONS
163	Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reproductive BioMedicine Online, 2010, 20, 768-775.	2.4	74
164	Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reproductive BioMedicine Online, 2010, 21, 360-365.	2.4	102
165	Misplaced obsession with prospectively randomized studies. Reproductive BioMedicine Online, 2010, 21, 440-443.	2.4	22
166	Further comments on the Suleman case. Expert Review of Obstetrics and Gynecology, 2010, 5, 501-502.	0.4	0
167	Association of <i>BRCA1</i> Mutations With Occult Primary Ovarian Insufficiency: A Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks. Journal of Clinical Oncology, 2010, 28, 240-244.	1.6	312
168	â€~Patient-friendly' IVF. Expert Review of Obstetrics and Gynecology, 2010, 5, 1-4.	0.4	2
169	FMR1 Genotype with Autoimmunity-Associated Polycystic Ovary-Like Phenotype and Decreased Pregnancy Chance. PLoS ONE, 2010, 5, e15303.	2.5	49
170	Can the FMR1 (Fragile X) Gene Serve As Predictor of Response to Ovarian Stimulation?. Reproductive Sciences, 2009, 16, 462-467.	2.5	18
171	Do etiologies of premature ovarian aging (POA) mimic those of premature ovarian failure (POF)?. Human Reproduction, 2009, 24, 2395-2400.	0.9	50
172	Correlation of triple repeats on the <i>FMR1</i> (fragile X) gene to ovarian reserve: A new infertility test?. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 1024-1030.	2.8	41
173	A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertility and Sterility, 2009, 91, 1700-1706.	1.0	82
174	A pilot study of premature ovarian senescence: II. Different genotype and phenotype for genetic and autoimmune etiologies. Fertility and Sterility, 2009, 91, 1707-1711.	1.0	46
175	Twin pregnancy, contrary to consensus, is a desirable outcome in infertility. Fertility and Sterility, 2009, 91, 2426-2431.	1.0	79
176	Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels. Fertility and Sterility, 2009, 91, 2616-2619.	1.0	66
177	Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertility and Sterility, 2009, 91, 1553-1555.	1.0	97
178	Dehydroepiandrosterone treatment of ovarian failure. Fertility and Sterility, 2009, 91, e14-e14.	1.0	5
179	Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. Reproductive BioMedicine Online, 2009, 19, 385-390.	2.4	82
180	Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reproductive Biology and Endocrinology, 2009, 7, 108.	3.3	104

#	Article	IF	CITATIONS
181	Is the immunological noise of abnormal autoimmunity an independent risk factor for premature ovarian aging?. Menopause, 2009, 16, 760-764.	2.0	13
182	Does autoimmunity play a role in the pathophysiology of premature ovarian ageing?. Reproductive BioMedicine Online, 2008, 16, 830-834.	2.4	9
183	Preimplantation genetic screening: "established―and ready for prime time?. Fertility and Sterility, 2008, 89, 780-788.	1.0	43
184	The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Human Reproduction, 2008, 23, 499-503.	0.9	48
185	Age-specific ovarian function. Expert Review of Obstetrics and Gynecology, 2008, 3, 595-600.	0.4	2
186	Androgen priming before ovarian stimulation for IVF. Human Reproduction, 2008, 23, 2868-2870.	0.9	6
187	Arguments against elective single-embryo transfer. Expert Review of Obstetrics and Gynecology, 2008, 3, 481-486.	0.4	8
188	Association of pelvic organ prolapse and fractures in postmenopausal women. Menopause, 2008, 15, 59-66.	2.0	34
189	Female infertility due to abnormal autoimmunity: frequently overlooked and greatly underappreciated. Part II. Expert Review of Obstetrics and Gynecology, 2007, 2, 465-475.	0.4	10
190	Differences in ovarian function parameters between Chinese and Caucasian oocyte donors: do they offer an explanation for lower IVF pregnancy rates in Chinese women?. Human Reproduction, 2007, 22, 2879-2882.	0.9	31
191	Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA - Journal of the American Medical Association, 2007, 297, 1465-77.	7.4	1,443
192	Age-Specific Levels for Basal Follicle-Stimulating Hormone Assessment of Ovarian Function. Obstetrics and Gynecology, 2007, 109, 1404-1410.	2.4	86
193	Update on the comparison of assisted reproduction outcomes between Europe and the USA: the 2002 data. Fertility and Sterility, 2007, 87, 1301-1305.	1.0	31
194	Aneuploidy rates in embryos from women with prematurely declining ovarian function: a pilot study. Fertility and Sterility, 2007, 88, 90-94.	1.0	34
195	Lack of association between polycystic ovary syndrome and embryonic aneuploidy. Fertility and Sterility, 2007, 88, 900-905.	1.0	71
196	Reply: The quality of residual follicles may depend on the etiology of "declining―ovarian function?. Fertility and Sterility, 2007, 88, 1481.	1.0	0
197	Gender as risk factor for autoimmune diseases. Journal of Autoimmunity, 2007, 28, 1-6.	6.5	284
198	Female infertility due to abnormal autoimmunity: frequently overlooked and greatly underappreciated. Part I. Expert Review of Obstetrics and Gynecology, 2007, 2, 453-464.	0.4	9

#	Article	IF	CITATIONS
199	Functional autoantibodies, a new paradigm in autoimmunity?. Autoimmunity Reviews, 2007, 7, 42-45.	5.8	58
200	Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. Journal of Assisted Reproduction and Genetics, 2007, 24, 629-634.	2.5	182
201	Too old for IVF: are we discriminating against older women?. Journal of Assisted Reproduction and Genetics, 2007, 24, 639-644.	2.5	27
202	The relative myth of elective single embryo transfer. Human Reproduction, 2006, 21, 1337-1344.	0.9	81
203	Calcium plus Vitamin D Supplementation and the Risk of Fractures. New England Journal of Medicine, 2006, 354, 669-683.	27.0	1,674
204	"Ovarian age-based―stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization. Fertility and Sterility, 2006, 86, 1621-1625.	1.0	32
205	Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Human Reproduction, 2006, 21, 2845-2849.	0.9	197
206	A formal comparison of the practice of assisted reproductive technologies between Europe and the USA. Human Reproduction, 2006, 21, 1945-1950.	0.9	53
207	Combined Analysis of Women's Health Initiative Observational and Clinical Trial Data on Postmenopausal Hormone Treatment and Cardiovascular Disease. American Journal of Epidemiology, 2006, 163, 589-599.	3.4	157
208	Symptom Experience After Discontinuing Use of Estrogen Plus Progestin. JAMA - Journal of the American Medical Association, 2005, 294, 183.	7.4	153
209	Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer, 2005, 104, 1520-1530.	4.1	99
210	Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial. American Journal of Epidemiology, 2005, 162, 404-414.	3.4	261
211	Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. Fertility and Sterility, 2005, 84, 374-383.	1.0	77
212	Increased oocyte production after treatment with dehydroepiandrosterone. Fertility and Sterility, 2005, 84, 756.e1-756.e3.	1.0	108
213	Retinoblastoma in a child conceived by in vitro fertilisation. British Journal of Ophthalmology, 2004, 88, 1098-1099.	3.9	16
214	Postthaw blastomere survival is predictive of the success of frozen?Thawed embryo transfer cycles. Fertility and Sterility, 2004, 82, 821-826.	1.0	30
215	Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (The Women's) Tj E	TQq1 1 0. 1.6	784314 rgB
216	Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures <subtitle>The Women's Health Initiative Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2003, 290, 1739.	7.4	466

#	Article	IF	CITATIONS
217	Habitual Tea Consumption and Risk of Osteoporosis: A Prospective Study in the Women's Health Initiative Observational Cohort. American Journal of Epidemiology, 2003, 158, 772-781.	3.4	95
218	Impaired Folliculogenesis and Ovulation in Older Reproductive Aged Women. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5502-5509.	3.6	111
219	Clinical Significance of Methohexital, Meperidine, and Diazepam in Breast Milk. Journal of Clinical Pharmacology, 1997, 37, 186-192.	2.0	34
220	Semen analyses in 1,283 men from the United States over a 25-year period: no decline in quality. Fertility and Sterility, 1996, 65, 1009-1014.	1.0	395
221	Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics, 1996, 13, 745-747.	2.5	40
222	Abnormal sperm morphology is highly predictive of pregnancy outcome during controlled ovarian hyperstimulation and intrauterine insemination. Journal of Assisted Reproduction and Genetics, 1996, 13, 569-572.	2.5	34
223	Levels of interferon-Γ and tumor necrosis factor-α in sera and cervical mucus of fertile and infertile women: implication in infertility. Journal of Reproductive Immunology, 1995, 29, 105-117.	1.9	39
224	Incidence of bowel injury due to dense adhesions at the sight of direct trocar insertion. Journal of reproductive medicine, The, 1992, 37, 617-8.	0.2	35
225	Infertility surgery by laparotomy. Current Opinion in Obstetrics and Gynecology, 1991, 3, 398-403.	2.0	1
226	The in vitro fertilization program at Albert Einstein College of Medicine, Bronx, New York. Journal of in Vitro Fertilization and Embryo Transfer: IVF, 1987, 4, 189-189.	0.8	0
227	The annual ovarian cycle of Chrysemys picta: Correlated changes in plasma steroids and parameters of vitellogenesis. General and Comparative Endocrinology, 1978, 35, 245-257.	1.8	168
228	Dehydroepiandrosterone. , 0, , 93-98.		2
229	The aging ovary. , 0, , 275-286.		1